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We conducted comprehensive reviews of published literature linking iron deficiency to disability and death for four potential outcomes: child mortality, perinatal mortality, maternal mortality and mild mental retardation. For all of these outcomes, the best available data were prospective observational studies in which anaemia or haemoglobin concentration was the risk factor. Data on child mortality were not adequate for this task, although a true risk cannot be precluded by the data. Summary relative risks for perinatal mortality (10 studies), maternal mortality (six studies) and mental retardation (five studies) were estimated using random effects models (both mortality outcomes) or a fixed-effects model (retardation) and weighting individual estimates by the inverse of their within-study variance. For mortality outcomes, the bivariate relations between haemoglobin and death were used. In two studies of perinatal mortality, unadjusted and multivariate adjusted odds ratios were compared to assess the potential degree of bias in the unadjusted associations. For mental retardation, published multivariate adjusted relations between haemoglobin and IQ were used. Global anaemia prevalence data were supplied by the World Health Organization (WHO), and converted to mean haemoglobin concentrations, assuming normal distribution and observed standard deviations from a large number of studies. To estimate the haemoglobin distribution if iron deficiency were corrected, we assumed the prevalence of anaemia in women and children would be reduced by 50%. On average, for the world, this would increase haemoglobin concentration by about 0.45 g/dl (range: 0.0 g/dl to 1.28 g/dl).
Introduction
Iron deficiency is one of the most prevalent nutrient deficiencies in the world, affecting an estimated two billion people (Stoltzfus and Dreyfuss 1998) . Young children and pregnant and postpartum women are the most commonly and severely affected because of the high iron demands of infant growth and pregnancy. However, where diets are based mostly on staple foods with little meat intake, or people are exposed to infections that cause blood loss (primarily hookworms and urinary schistosomiasis), iron deficiency may occur throughout the life span. Current WHO/International Nutritional Anemia Consultative Group/United Nations Children's fund/United Nations Children's fund (WHO/INACG/UNICEF) guidelines recommend universal iron and folic acid supplementation of young children and pregnant women where anaemia is highly prevalent (Stoltzfus and Dreyfuss 1998) . Although much is known about iron metabolism, the health consequences of iron deficiency continue to be a subject of research and debate. This is partly because in many regions of the world iron supplements are the standard of care for individuals with anaemia. Most trials of iron supplementation have measured haemoglobin concentra-tion as the primary outcome. There is a relatively small body of clinical trials of iron repletion to humans with functional iron deficiency (i.e. iron deficiency severe enough to affect erythropoiesis) with pregnancy outcomes or mortality as primary objectives. There is surprisingly little evidence to either support or refute a causal link between iron deficiency and these important adverse health outcomes. As processes like this comparative risk assessment (CRA) bring to light the overall weakness of evidence either supporting or refuting the relationship, new research priorities may emerge.
2.
Health outcomes considered
In May 2000, a meeting commissioned by WHO, INACG and the Edna McConnell Clark Foundation systematically reviewed the evidence of a causal relationship between iron deficiency or anaemia and six health outcomes: child mortality, maternal mortality, birth outcomes, morbidity, work productivity and child development. These papers were subsequently published in a supplement to the Journal of Nutrition (Beard and Stoltzfus 2001) . We began by considering those six outcomes. Malnutrition (in this case, iron deficiency) may contribute to death and disability through direct sequelae or as a risk factor for death and disability from other causes. The total death and disability attributed to iron deficiency is therefore the sum of its actions as a risk factor and its direct sequelae. The objective of the present paper is to consider iron deficiency as a risk factor for death and disability from other causes.
Of the six outcomes considered above, child mortality, maternal mortality, birth outcomes and morbidity were considered in the framework of iron deficiency as a risk factor. For example, women do not die in childbirth as a direct effect of iron deficiency, but rather die of heart failure due to blood loss, which is made more precipitous by iron deficiency anaemia. Similarly, babies do not die in the perinatal period from iron deficiency, but rather die of other causes, some of which are related to preterm birth, for which maternal iron deficiency is a risk factor. In contrast, decreased work productivity and altered child development (or intelligence) were considered to be direct sequelae of iron deficiency, the assumption being that iron deficiency directly causes decreased oxygen delivery to muscles and the brain.
2.1
Outcomes considered
CHILD MORTALITY
There is a body of observational evidence linking child mortality to anaemia. However, we could find no published or unpublished studies of reasonably large size that described the relationship between anaemia and cause-specific mortality. Furthermore, nearly all the evidence linking anaemia to overall mortality comes from sub-Saharan Africa or Papua New Guinea, where P. falciparum malaria is a major cause of anaemia, especially severe anaemia, and malaria is also a major cause of mortality. Thus it seemed unjustified to attribute the observed relationship between anaemia and mortality to iron deficiency in this context, or to generalize to other regions of the world. Brabin et al. (2001a) summarized these data and their interpretation. There are no observational studies linking iron deficiency per se to child mortality, nor any iron supplementation trials with child mortality as outcome. For these reasons, we were unable to estimate the relationship between iron deficiency and cause-specific child mortality. However, it is important to note that the available evidence does not preclude that relationship.
MATERNAL MORTALITY
There are a number of observational studies of anaemia and maternal mortality from both Africa and Asia. None of these studies attempted to distinguish iron deficiency anaemia from other causes of anaemia, although several discussed the multiple causes of anaemia within their study population. Where P. falciparum malaria is endemic, it is an important cause of anaemia, especially in first pregnancies (Brabin 1983) . However, there is no evidence that malarial infection contributes directly to maternal mortality, even in areas where P. falciparum is endemic (Brabin et al. 2001b ). Thus in contrast to the situation with child mortality, it is less plausible that malaria would confound the observed relationship between anaemia and maternal mortality (as it likely does with anaemia and child mortality). There are no observational studies linking iron deficiency per se to maternal mortality, nor are there any iron intervention trials with maternal mortality as outcome. Thus we used the available observational data to estimate the relationship between anaemia and maternal mortality.
PERINATAL MORTALITY
There are several observational studies of maternal anaemia and stillbirths, neonatal or perinatal mortality from Africa, Asia, North America, and the United Kingdom of Great Britain and Northern Ireland. None of these studies attempted to distinguish iron deficiency anaemia from other causes linking anaemia. There are no observational studies linking maternal iron deficiency per se to perinatal mortality, and the few published iron intervention trials with perinatal morality as outcome are small or poorly designed. As with maternal mortality, we used the available observational data to estimate the anaemia-perinatal mortality relationship.
LOW BIRTH WEIGHT
We did not consider low birth weight as a separate outcome in these analyses, but rather assumed that the mortality risk and morbidity burden of anaemia-associated low birth weight was subsumed in our estimate of perinatal mortality as outcome. The relationship between iron status and low birth weight has been examined in several clinical trials, and it has been the subject of two recent systematic reviews (Mahomed 2000a; Rasmussen 2001) . Both concluded that causal evidence from trials is lacking. Rasmussen (2001) noted that there was insufficient evidence from these trials either to support or refute the relationship, because most trials conducted in populations with a significant burden of anaemia have suffered from poor research designs. There is however a substantial body of observational data relating pregnancy anaemia to low birth weight, similar to the observational data relating pregnancy anaemia to maternal and perinatal mortality. Scott Poe and Mary Cogswell (personal communication) have recently completed a meta-analysis of these observational studies. They found that pregnancy anaemia assessed in the first two trimesters of pregnancy was significantly associated with preterm birth (but not intrauterine growth retardation), and that the risk of preterm birth increased with increasing severity of anaemia.
2.2
Outcomes considered to be direct sequelae of iron deficiency
WORK PRODUCTIVITY
There is a substantial body of evidence in animals and humans demonstrating that iron deficiency decreases fitness and aerobic work capacity through mechanisms that include oxygen transport and respiratory efficiency within the muscle (Beard 2001; Haas and Brownlie 2001) . This relationship is directly and linearly related to the severity of iron deficiency anaemia. The personal and socioeconomic consequences of this relationship are likely to be real and measurable (Horton and Levin 2001) . This consequence of iron deficiency is estimated as a direct sequela of iron deficiency, and is not presented here as a risk factor.
INTELLIGENCE OR COGNITIVE CAPACITY
There is a growing body of evidence from animal and human studies that supports a causal relationship between iron deficiency anaemia in early childhood and intelligence in mid-childhood (Beard 2001; Grantham-McGregor and Ani 2001) . Although this effect of iron deficiency will be considered as a direct sequela of iron deficiency, we used the observational studies of iron deficiency anaemia in early childhood and measures of intelligence in mid-childhood to obtain a quantitative estimate of this relationship. Different investigators used different measures of cognition, learning or intelligence, making it impossible to summarize all the results. We therefore limited the outcome to global measures of intelligence that were either IQ or on the same scale as IQ (i.e. mean of 100 with standard deviation of 15 points). However, all of these studies measured deviations in intelligence within the clinically normal range (i.e. ≥70 points). In terms of the International Statistical Classification of Diseases and Related Health Problems, ninth revision (ICD-9) classification, disability in this domain is limited to mental retardation, which these studies do not directly address. We have therefore provided an estimate of the effect of early iron deficiency on mental retardation in mid-childhood, making the controversial assumption that the reported association of iron deficiency anaemia and mean IQ does not affect the variance of IQ. Based on this assumption we can estimate the expected increased risk of IQ <70 (i.e. mild mental retardation) associated with shifts in mean IQ.
MORBIDITY
The bulk of experimental evidence from iron supplementation trials regards morbidity. There is evidence that sufficient iron is essential for immune function (Beard 2001) , and also that excess iron may exacerbate some diseases. The evidence from experimental trials does not suggest that iron supplementation reduces morbidity; in some cases it has been associated with increased morbidity, most notably malaria and respiratory infections in malarious areas (Oppenheimer 2001) . However, it is most plausible that this excess risk is associated with therapeutic iron supplementation intended to treat iron deficiency; not that iron deficiency itself is beneficial. Those trials that used low-dose oral supplementation in currently recommended dosages found no adverse effect (INACG 1999) . Therefore, we did not estimate a morbidity risk associated with iron deficiency; nor does the available evidence support a risk associated with the correction of iron deficiency by currently recommended public health strategies. To summarize, we have presented estimates of risk relationships for maternal mortality and perinatal mortality. These were based on anaemia as the indicator of iron deficiency, and only a proportion of that risk is therefore attributed to iron deficiency. We have also presented an estimate of the relationship between iron deficiency anaemia, decreased IQ and mental retardation, although we believe it should be interpreted with extreme caution.
3.
Nature and definition of the risk factor
Iron is required in all tissues of the body for cellular respiration and many other reduction-oxidation enzyme systems, and has particular functions in muscle, brain and red cells. Critical metabolic functions in these three organs become perturbed at about the same time as animals are depleted of iron (Beard 2001) . Anaemia has been used as the hallmark of iron deficiency severe enough to affect tissue function, because red cells are the tissue most amenable to sampling. Although more specific indicators of functional iron deficiency are available, notably erythrocyte protoporphyrin and serum transferrin receptor, there is insufficient data to link those indicators to the health outcomes that fit the construct of this project, namely maternal and perinatal mortality.
It is problematic that all of the available data on maternal and perinatal mortality use anaemia as the indicator, because iron deficiency is not the sole cause of anaemia in most populations. Even within individuals, anaemia may be caused by multiple factors. The available studies do not attempt to separate iron deficiency from anaemia, and there are no good regional estimates of the proportion of anaemia attributable to iron deficiency, although the topic has been discussed and debated (Gillespie and Johnston 1998) .
We therefore took the approach of estimating the risk function associated with low haemoglobin, using haemoglobin as a continuous variable. Where studies reported haematocrit instead of haemoglobin, we converted to haemoglobin by dividing haematocrit by 3.
Because our task was to estimate the burden due to iron deficiency, the counterfactual (i.e. theoretical minimum) distribution should therefore represent the haemoglobin distribution if iron deficiency were eliminated. We assumed that the change in haemoglobin distribution following a supervised period of iron supplementation was a conservative approximation of the virtual elimination of iron deficiency.
1 By conservative we mean that it is more likely to underestimate the contribution of iron deficiency than to overestimate it, due to problems of noncompliance with supplementation, insufficient dosage, or insufficient duration.
We approached this calculation from two angles. The first approach was to estimate the percentage of anaemia attributable to iron deficiency. Knowing this, we could estimate the shift in the haemoglobin distribution needed to reduce anaemia by that proportion. Beaton recently summarized the per cent reduction in anaemia observed in nine controlled supplementation trials, all conducted in children (Table 3 .1). The range of values was wide, 21-85%. Although there is regional diversity in the studies, these data are not sufficient to generate regional estimates. They provide a global average of 51%.
A second and complementary approach was to examine mean changes in haemoglobin attributable to iron supplementation in iron supplementation trials. Sloan et al. (2002) conducted a meta-analysis of haemoglobin response to iron supplementation to pregnant women in randomized controlled trials. Of 70 trials in the literature, 23 met their inclusion criteria, and 15 of those were from developing countries. In studies from developing countries, haemoglobin response was smaller in study samples with higher initial haemoglobin (summarized mean change of 1.13 g/dl in those with initial mean haemoglobin <10.0 g/dl compared to 0.85 g/dl in those with haemoglobin 11.0-11.9 g/dl). However, in studies from developed countries, the initial haemoglobin concentrations were uniformly ≥11.0 g/dl, and the effect size was large (1.17 g/dl). The response to iron supplementation was strongly related to iron dose, with maximum effects observed in the eight studies that provided a daily dose ≥91 mg. In these studies the mean haemoglobin response was around 1.8 g/dl. This maximal response might be considered the best theoretical basis for predicting the effect of eradicating iron deficiency. However, it is likely that the highest doses were also used in studies of more severely anaemic populations. A case can also be made for using 1.17 as the predicted effect size, as this was the average effect seen in women from developed countries, and very similar to that seen in women from developing countries with initially low haemoglobin (1.10-1.13 g/dl).
An important question for the present exercise is whether the predicted haemoglobin shift should vary by region. Sloan et al. (2002) did not disaggregate their data by global region, and the studies examined by Beaton are too few to disaggregate (see Table 3 .1). If significant regional differences exist in the percentage of anaemia attributed to iron deficiency, the iron-attributable portion might be smaller in Africa, where malaria contributes greatly to the burden of anaemia. Therefore iron would logically claim a smaller portion of total anaemia. Shankar recently summarized data from controlled iron supplementation trials conducted in P. falciparum malaria-endemic populations, including the haemoglobin response attributable to iron (INACG 1999) . Eleven studies were included, nine of them from sub-Saharan Africa (Adam 1997; Fleming et al. 1986; Harvey et al. 1989; Lawless et al. 1994; Menendez et al. 1994 Menendez et al. , 1997 Murray et al. 1978; Oppenheimer et al. 1986; Smith et al. 1989) . The studies included younger and older children, and adults, including pregnant women. The change in haemoglobin attributable to iron supplementation in individual studies ranged from 0.3 to 3.6 g/dl, yielding a weighted average of 1.24 (95% CI 1.16-1.33). Although malaria certainly contributed to anaemia in these populations, it is Source: Beaton (2002) .
remarkable that the haemoglobin response to iron supplementation was similar to that reported by Sloan et al. (2002) . Two of the 11 studies in the Shankar analysis were in pregnant women-the subject of analysis by Sloan et al. and the group at risk for the outcomes estimated in this chapter. These two studies from the Shankar analysis both used an iron dose of 60 mg/day, and yield a weighted average haemoglobin response of 0.83 g/dl. These studies were excluded from the analysis by Sloan et al., but are consistent with the haemoglobin responses at the dosage reported by them: 0.41 in studies of doses £60 mg/day, and 0.86 in studies of doses 61-90 mg/day. Thus, the data suggest that iron deficiency is responsible for about 50% of anaemia, and that, where anaemia is prevalent, elimination of iron deficiency results in a change in mean haemoglobin of about 1.17 g/dl or perhaps even higher. The data are lacking in several respects: notably, the studies included in these three meta-analyses did not include non-pregnant adults outside of Africa. From the data at hand, there is no strong basis for altering these values by region. We used both of these lines of evidence to estimate the proportion of the risk associated with anaemia that is attributable to iron deficiency (see section 8).
4.
Search strategy
Maternal mortality
We based our work on the recent systematic review by Brabin et al. (2001b) . Because there are no experimental trials of iron deficiency and maternal mortality, we estimated the risk relationship from observational data. As described by Brabin et al. (2001b) , several studies from Nigeria have documented extremely high risks of maternal mortality at haemoglobin concentrations <5 g/dl. We decided to limit our description of the haemoglobin-mortality risk relationship to the haemoglobin range of 5-12 g/dl. Values <5 g/dl are rare on a population basis, being more than 2 standard deviations below the mean in even the most severely anaemic communities, and we did not want those data to influence our risk estimates for the common population ranges. Pregnancy haemoglobin values >12 g/dl were excluded because we judged that variation in this high range is mostly unrelated to iron status, and our ultimate objective was to estimate risk associated with iron deficiency. We thus included those studies that reported mortality rates in at least two haemoglobin groups in the range of 5-12 g/dl rates. This excluded three studies: Fullerton and Turner (1962) , Johnson and Ojo (1967) and Tasker (1958) . We further excluded the study of Chi et al. (1981) from Indonesia, because the haemoglobin categories presented in their Table 5 disagreed with that in the text and we had no basis for determining which was correct. In summary, 10 studies were identified, and six of these were included in the meta-analysis (see Table 3 .2 for study descriptions). 
Perinatal mortality
As with maternal mortality, we estimated the risk relationship from observational studies, using pregnancy or delivery maternal haemoglobin concentration as the risk factor. Published trials of iron supplementation that reported perinatal or neonatal mortality as an outcome were not used as a basis for our risk estimate because the women in the trial were not anaemic (Hemminki and Rimpelä 1991) or because they were small or poorly designed to test the effect of iron (Agarwal et al. 1991; Fleming et al. 1986 ). We based our search on the recent systematic reviews of Brabin et al. (2001b) , Rasmussen (2001) and Xiong et al. (2000) . We added to this one unpublished study by Dreyfuss et al. in which one of us was involved. Xiong et al. described the relationship between pregnancy anaemia and perinatal outcomes in 16 936 women in China. This study is published only as an abstract ; however, the authors provided the data we needed to include here. In summary, 13 studies were identified and 10 were included in the meta-analysis (see Table 3 .3 for study descriptions).
4.3
Child development
We based our work on the recent systematic review by GranthamMcGregor and Ani (2001) . We were interested in estimating the risk of continuous decrement in cognitive function or capacity in children who were iron-deficient anaemic in early childhood. Thus we limited our meta-analysis to those studies that identified iron-deficient anaemic and non-anaemic infants and toddlers and then compared their intelligence at age 2-7 years. We further limited the meta-analysis to studies that used standardized tests on a scale of 100 with standard deviation 15 (i.e. IQ tests and the Bayley Mental Development Index). Seven different longitudinal studies were described by Grantham-McGregor and Ani (Table 3 .4). The study by Hurtado et al. (1999) was excluded because the outcome measure was placement in special education, rather than a measure of intelligence. Similarly, the study by Dommergues et al. (1989) was excluded because the outcome measure (Brunet-Lezine test) did not meet our criterion for a summarizable outcome. The two longitudinal studies by Lozoff et al. followed the same cohort of children; the data from the 1991 publication were used in this analysis. The two studies of Wasserman et al. also followed the same cohort of children. The data from the 1992 publication were used in this analysis because nearly 40% of the cohort was lost to follow-up by the time of the evaluation of the children at four years of age in the 1994 publication. The five studies that were included in our meta-analysis are described in Table 3 .4. 
5.
Methods for combining risk estimates from individual studies
Anaemia and maternal mortality
In each study, maternal mortality data were given in aggregate for each of the ranges. All ranges were converted to haemoglobin by dividing haematocrit values by 3. The midpoint of each range was used as the independent variable. The midpoints were estimated from the information provided in the articles. A logistic regression model was then used to fit the observed data, weighting each haemoglobin midpointmortality point by the total number of women in that range. Within each study, an estimate of the risk ratio associated with a one-unit difference in haemoglobin was calculated. These individual estimates were initially combined in a fixed-effects model, weighting individual estimates by the inverse of their within-study variance, to estimate an overall risk ratio. The heterogeneity statistic indicated that individually observed effect sizes varied significantly around the overall fixed-effects model estimate.
Dropping the assumption of a fixed-treatment effect, the individual effect sizes were then assumed to be normally distributed and a random-effects combined estimate was calculated using the method of DerSimonian and Laird (1986).
Anaemia and perinatal mortality
Analyses for perinatal mortality were conducted in a similar manner as that for maternal mortality. The nine studies included in the metaanalysis were sufficiently heterogeneous that a random-effects model was used to generate combined estimates (DerSimonian and Laird 1986).
Iron deficiency anaemia and child intelligence
The beta coefficients from multivariate regression models associated with a 1 g/dl change in haemoglobin were obtained directly from the original published paper (Palti et al. 1983; Wasserman et al. 1992) or estimated indirectly from means and P-values (Cantwell 1974; de Andraca et al. 1990; Lozoff et al. 1991) . Standard deviations were obtained directly from the original paper (Wasserman et al. 1992) , estimated from Pvalues and beta coefficients (de Andraca et al. 1990; Lozoff et al. 1991; Palti et al. 1983) , or estimated by assuming a significance level of 0.05 (Cantwell et al. 1974) . As original data were not available, variability in baseline anaemia levels was not considered; rather, baseline mean haemoglobin levels were compared to follow-up IQ scores with standard deviations to estimate individual study regression coefficients. The estimates were combined in a fixed-effects model, weighting studies according to the reciprocal of their within-study variance. A chi-squared test for heterogeneity found no significant between-study variance; thus a randomeffects model was not necessary.
6.
Results

Maternal mortality
We computed odd ratios for maternal mortality associated with a 1 g/dl increase in pregnancy haemoglobin. Of the six studies included in our meta-analysis, all had individual study ORs <1.0, and three of those were statistically significant (Table 3 .5 and Figure 3 .1). The estimated OR from combining data points from all the studies was 0.75, with a CI that clearly excluded unity (0.62-0.89). The studies were not geographically diverse, coming from only three countries (India, Malaysia and Nigeria).
However there was not a systematic difference between the risk estimates from the Nigerian vs the Asian studies. Two Nigerian studies had markedly lower ORs than the other four studies; however these two studies carried little weight in the combined OR.
Perinatal mortality
Ten studies were included in our meta-analysis. The individual ORs for perinatal mortality associated with a 1 g/dl increase in haemoglobin ranged from 0.55 to 0.87 (Table 3 .6 and Figure 3 .2). Nine of the 10 individual study estimates were statistically different from unity. The estimated OR from the 10 studies combined was 0.72 (95% CI 0.65-0.81). The nine studies included in the meta-analysis were sufficiently heterogeneous that a random-effects model was used to generate combined estimates. We explored three factors that might explain this heterogeneity; these subgroup analyses are presented in Table 3 .7. First, we were liberal in accepting various outcome definitions related to perinatal mortality. Only three of the 10 studies used the correct definition, which includes fetal death after 22 (or 28) weeks' gestation and neonatal mortality in the first seven days of life. Use of the correct definition of Kenya 1963; Malaysia 1965; Nepal 1998 , Nigeria 1975 , 1976 Papua New Guinea 1999 . d Kenya 1963 Nigeria 1975 Nigeria , 1976 Nigeria , 1985 perinatal mortality did not significantly change the effect estimate. Second, P. falciparum malaria contributes to anaemia in pregnancy and may also affect perinatal mortality. Five of the studies were conducted in populations with endemic P. falciparum malaria, and these studies had a combined risk estimate that was substantially further from unity than those studies conducted in populations not heavily exposed to this form of malaria. We concluded that the risk relationship with anaemia is greater in P. falciparum malaria-endemic regions. Third, two studies assessed haemoglobin at delivery whereas the other eight assessed haemoglobin earlier in gestation. Xiong et al. (2000) have suggested that anaemia early in pregnancy carries a greater risk of adverse perinatal outcomes; however this inference was based on low birth weight as outcome. We did not find this in our data. In fact, the risk relationship was slightly stronger in the two studies that assessed haemoglobin at delivery. However, those two studies were also in P. falciparum malariaendemic populations, which could bias the analysis. The ORs presented in Table 3 .6 and Figure 3 .2 are unadjusted for potential confounding factors. Two of the 10 studies, Nepal 1998 and China 1996, could provide us with both unadjusted and adjusted ORs by haemoglobin category. These are displayed in Table 3 .8. In the Nepal study, multivariate adjustment for a number of variables had no effect on the estimated ORs. However, in the China study, in which more covariates were measured, multivariate adjustment attenuated the ORs by about 20%.
We have therefore attenuated the ORs for both perinatal and maternal mortality by 20%, as the evidence at hand suggests that the unadjusted estimates may be overestimated to about that degree. The final ORs and confidence intervals used to generate the burden of disease estimates are shown in Table 3 .9.
6.3
Child intelligence
Five studies were included in our meta-analysis. The studies were geographically diverse, including Europe, Latin America, the Middle East and North America (the United States of America). However, there were no studies included from Africa or Asia. We estimated the expected change in IQ points associated with a 1 g/dl change in haemoglobin. The individual study estimates ranged from 1.36 to 2.52, and all were statistically different from zero (Table 3 .10 and Figure 3. 3). The combined estimate was 1.73 points, with a 95% CI of 1.04-2.41. The quality of the studies was high, and all of them provided estimates that were adjusted for multiple covariates. The relevant disease outcome for this analysis would be mild mental retardation, defined as IQ <70, or more than 2 standard deviations below the expected population mean of 100. The increase in risk of mental retardation can be estimated from the expected mean change in IQ if one assumes that the mean change represents a shift in the entire distribution of values with no change in variance of the distribution. These calculations are displayed in Table 3 .10. The resultant relative risk associated with a 1 g/dl increment in haemoglobin concentration is 0.78. The relative risk estimates associated with the upper and lower confidence limits of the estimated change in IQ are 0.70 and 0.86, respectively (Table 3 .11).
7.
Description of malnutrition tables
To describe the distribution of low haemoglobin by region we used the anaemia prevalence data that were published in the 1990 Global Burden 
Wasserman et al. (1992) of Disease (GBD) books (Murray and Lopez 1996a, 1996b) . This database is currently being revised and updated, but the complete new data will not be available within the time frame of this project. We applied the following steps: (i) converted the prevalence data from the GBD 1990 regions to the subregions 2 used currently; (ii) converted data on prevalence of anaemia into mean haemoglobin values; and (iii) estimated the counterfactual haemoglobin distribution, representing the elimination of iron deficiency.
The anaemia database that we used was based on surveys conducted prior to 1990. Global monitoring of anaemia trends suggests that the prevalence of anaemia in the world has not decreased in the past decade (UNICEF 1998). However, the representativeness and reliability of these data (in terms of sample sizes) are less than we would hope for. Table  3 .12 summarizes the numbers of country surveys included in the available data set, and the conversion from previous regions to the subregions used in the present analysis. Data for EUR-B and EUR-C are especially scarce. In the case of SEAR-D, the previous data source included only one country, India, but several surveys contributed to the country estimate.
Nationally representative anaemia data from the United States are available that are more recent than the data in the 1990 WHO database, and demonstrate lower anaemia prevalences (Looker et al. 1997 ). So as not to overestimate the burden of anaemia in economically developed regions, we used these data from the United States for three subregions, AMR-A, EUR-A and WPR-A. The haemoglobin cut-offs used to define anaemia globally have not changed since the 1990 database was created (Table 3 .13). The resulting anaemia prevalence estimates are given in Table 3 .14.
The second step was to convert the prevalence of anaemia to a mean haemoglobin value. We assumed all haemoglobin distributions to be approximately normal (Yip et al. 1996) . We then needed to make For these subregions, recent nationally representative data from the USA were used (Looker et al. 1997) . Table 3 .13 Haemoglobin cut-offs to define anaemia in populations living at sea level
Population group Haemoglobin cut-off (g/l)
Children 0-4 years 110
Children 6-14 years 120
Non-pregnant women 120
Pregnant women 110 Men 130
Source: Stoltzfus and Dreyfuss (1998) .
assumptions about the standard deviation of the distributions. The standard deviation of haemoglobin in a population depends on at least two factors. The first factor is the proportion of individuals who are at their homeostatic haemoglobin concentration (i.e. non-anaemics). There is a certain amount of variability in haemoglobin that is set by individual characteristics, including genetics. This would be represented by the standard deviation in a population with no anaemia. Added to this "inherent" variability is the variability associated with non-physiologic states, including iron deficiency. Thus it is logical to expect the standard deviation of haemoglobin to be higher in populations with more anaemia compared to those with infrequent anaemia. The second factor is the precision of the haemoglobin assay, with greater precision yielding smaller observed standard deviations. The variation in haemoglobin standard deviations is illustrated in Table 3 .15, which relates the prevalence of anaemia to the standard deviation, using data from a draft version of the updated (but still incomplete) anaemia database for the WHO African and Eastern Mediterranean Regions (B. de Benoist, personal communication) and data from the most recent national health and nutrition examination survey in the United States, after excluding iron-deficient individuals. The standard deviations from the data from the United States are significantly smaller, 
probably due to both of the factors discussed above. Namely, the proportion of anaemic individuals in this United States sample was very low, and the haemoglobin assessment method (venous blood collection, laboratory-based assay with rigorous quality control) was more precise than most field-based studies in developing countries. Based on these considerations, we assumed certain standard deviations based on the anaemia prevalence of each population group. These are given in Table 3 .16.
Knowing the proportion below a certain haemoglobin cut-off (i.e. prevalence of anaemia in a population) and the standard deviation of the normal distribution, we estimated the mean haemoglobin associated with the current prevalence of anaemia (Snedecor et al. 1980) . These values are given in Table 3 .17.
We then estimated the theoretical-minimum-risk distribution, representing the haemoglobin distribution if iron deficiency were eliminated. Assuming that 50% of anaemia in the world is attributable to iron deficiency (see section 3), we divided the current anaemia prevalences by 2. Because anaemia cut-offs are defined as the 5th percentile of a normative reference distribution (i.e. the distribution of individuals known to be free of disease), we set the minimum prevalence of anaemia in all world subregions to be 5.0%. We assumed a normal distribution, and applied the standard deviations in Table 3 .15. This yields values in Table  3 .18.
To check the plausibility of this theoretical minimum distribution, we examined the shift in population mean haemoglobin concentration from current reality to the theoretical minimum, representing the eradication of iron deficiency. These shifts are summarized in Table 3 .19.
The predicted shifts in mean haemoglobin ranged from 0.0, in young adult men in affluent subregions, to 1.28 g/dl in children in SEAR-D. The predicted haemoglobin shift for young children in AFR was 1.17, which is consistent with the evidence from iron supplementation trials in the P. falciparum-endemic populations (1.24, 95% CI 1.16-1.33, see section 3). The predicted haemoglobin shifts for women of reproductive age range from 0.11 to 1.17 g/dl. These estimates were somewhat lower than the average haemoglobin response of pregnant women to iron supplementation (0.85 to 1.17 g/dl), and were substantially lower than the haemoglobin responses in women provided iron doses of ≥90 mg/day (i.e. 1.8 g/dl) estimated by Sloan et al. (2002) . We are thus faced with some uncertainty about how to estimate the haemoglobin shift that would occur if iron deficiency were eliminated. Basing our estimates on a 50% reduction in anaemia yields a smaller shift than we would obtain if we assumed that the responses of pregnant women to maximal daily iron doses in the trials summarized by Sloan al. (2002) represented the true effect. We used the 50% reduction in anaemia for two reasons. First, it yields more conservative estimates for the overall burden of disease attributable to iron deficiency. Second, we expect that the responses seen in iron supplementation trials are not representative of all women in the region in which they were conducted. Researchers frequently select study populations that are unusual in their potential to respond to an intervention; in this case populations that are more anaemic than the average population. Therefore it is reasonable to expect that data from randomized trials would overestimate global or regional average effects.
A final consideration is that these global tables report values for all women in the reproductive age ranges, whereas the risks of perinatal and maternal mortality apply uniquely to pregnancy anaemia. Population surveys that include both pregnant and non-pregnant women demonstrate a strong linear correlation between the haemoglobin values in these two population subgroups, as shown in Figure 3 .4. Across the range of haemoglobin for women in Table 3 .17, the difference between haemoglobin values in non-pregnant and pregnant states is nearly constant (range: 1.39 g/dl to 1.34 g/dl). The haemoglobin cut-off used to define anaemia is also lower in pregnancy. The WHO cut-off, for simplicity, is 1.0 g/dl lower in pregnancy. However, the physiologic haemodilution of pregnancy reduces the haemoglobin concentration by 1.5 g/dl in midpregnancy (Institute of Medicine 1990), when many pregnancy values are obtained in field surveys. Thus we can expect the prevalence of true anaemia to be approximately the same in pregnant and non-pregnant women. Because pregnant women are more iron-deficient than non-pregnant women, there is reason to believe that the iron-attributable fraction of anaemia would be higher in pregnancy than in other states. However, lacking firm data on this relationship, we have made the conservative assumption that the anaemia prevalence and predicted haemoglobin shift associated with the elimination of iron deficiency are the same for pregnant women as non-pregnant women. 8.
Burden of disease estimates
The estimated deaths and DALYs attributable to iron deficiency are shown in Tables 3.20 and 3 .21. Those attributed to iron deficiency as a risk factor for perinatal and maternal conditions are shown separately from those attributed directly to iron deficiency anaemia. For perinatal and maternal conditions, only mortality (as opposed to morbidity) from maternal conditions was attributed to iron deficiency. In the absence of any data on anaemia and morbidity related to childbirth or the puerperium, we assumed that such a relationship did not exist. As discussed earlier, the effects of iron deficiency anaemia on work productivity and child development and cognition are included in the direct attributions to iron deficiency anaemia (i.e. in the iron deficiency anaemia columns). These direct estimates are updated from the 1990 GBD (Murray et al. 1996a (Murray et al. , 1996b , using 2000 demographic statistics, but otherwise the same methods. The total burden of death and disability attributable to iron deficiency is higher than the 1990 estimate. This is due to differences in the risk estimates, not the prevalence estimates, which remain unchanged. The inclusion of iron deficiency anaemia as a risk factor for perinatal mortality is new, and contributes substantially to estimated deaths and DALYs lost. Furthermore, in the 1990 estimate, deaths from iron defi- ciency anaemia were included only as "direct" deaths due to severe and very severe anaemia. The increased maternal mortality from iron deficiency anaemia as an underlying risk factor is newly included in these estimates. It is apparent that while the death and especially the disability directly attributable to iron deficiency anaemia is large, death and disability attributable to iron deficiency anaemia acting as a risk factor for perinatal and maternal causes is much larger. Because of the great numbers of perinatal deaths globally, perinatal causes account for 70% of the total deaths and 56% of the total DALYs attributable to iron deficiency anaemia. Numbers of maternal deaths, while very high, are much lower than perinatal deaths. Therefore the absolute contribution of maternal causes to the totals is smaller, namely 10% of DALYs and 14% of deaths. The relative contribution of maternal and perinatal causes to the total DALYs lost is largest where death rates are high (e.g. 80% in SEAR-D compared to only 25% in EUR-A). Indeed, as expected, the contribution of iron deficiency anaemia to maternal deaths is zero in AMR-A, EUR-A and WPR-A, where maternal mortality rates are very low.
When examined by region, the global burden of iron deficiency anaemia and its consequences are most heavily borne by those in SouthEast Asia and Africa. For maternal causes, 43% and 37% of the mater- This needed acceleration of effort did not take place. A more recent progress report (WHO 2000) concluded the following:
Unfortunately, there has been little appreciable change over the last two decades in the high worldwide prevalence of iron deficiency anaemia. Few active programmes in both developed and developing countries have succeeded in reducing iron deficiency and anaemia. Important factors contributing to the lack of progress include failure to recognize the causes of iron deficiency and anaemia, lack of political commitment to control it, inadequate planning of control programmes, insufficient mobilization and training of health staff, and insufficient community involvement in solving the problem.
Thus the evidence strongly suggests that under a "business-as-usual" scenario, the prevalence of iron deficiency anaemia will not decrease over the next decade. We hope that the new estimates of the burden of disease attributed to iron deficiency will result in a significant deviation from business-as-usual.
Discussion
Our analysis of the relationship between pregnancy anaemia and maternal mortality differed from that of the recent analysis by Brabin et al. (2001b) , although we drew upon the same published studies. The salient difference is that we began by estimating the mortality-haemoglobin relationship within each study (expressed as an OR per g/dl increment in haemoglobin), and then used meta-analytic techniques to obtain a weighted average of those ORs. Restricting the analysis to observations between 5 and 12 g/dl haemoglobin, the risk increased with decreasing haemoglobin within each study.
As noted previously, there are no trials of iron supplementation with maternal mortality as outcome. Furthermore, because of cost and ethical considerations, we will likely have to continue to rely on observational data to refine these estimates. However, better observational data are badly needed. The currently available data are generally quite old, are predominantly from Asia (India and Malaysia) and are not controlled for many potentially confounding or modifying factors.
This analysis differs from most previous statements about anaemia and maternal mortality by positing a continuous relationship between haemoglobin concentration and mortality risk. INACG issued the following statement about severe anaemia and death in childbirth (1989):
At 6.0 g/dl, evidence of circulatory decompensation becomes apparent. Women experience breathlessness and increased cardiac output at rest. At this stage, added stress from labor . . . can result in maternal death. Without effective treatment, maternal death from anemic heart failure . . . is likely with a haemoglobin concentration of 4.0 g/dl. Even a blood loss of 100 ml can cause circulatory shock and death.
A more recent summary statement (Stoltzfus 2001) , based on the systematic review of Brabin et al. (2001b) also concluded that "A significant body of causal evidence exists for . . . severe anaemia and maternal mortality" but that "causal evidence is lacking or contradictory for . . . mild-moderate anaemia and maternal mortality" (Table 1 ). However, considering that death from cardiovascular causes is a function of blood volume, blood loss, cardiac fitness and haemoglobin concentration, it seems plausible that the relationship between haemoglobin concentration and maternal death would be continuous in nature, although not necessarily linear. Indeed the relationship as we have modelled it in this analysis is log-linear, with risk increasing exponentially with decreasing haemoglobin concentration.
We are not aware of another systematic analysis of the observational data linking pregnancy anaemia to perinatal mortality. The risk estimates from geographically diverse studies were remarkably consistent, and we believe provided the best evidence available for our purpose. Rasmussen (2001) identified four controlled iron supplementation trials that reported perinatal deaths as an outcome. All four studies had major design concerns (low rates of follow-up or lack of anaemic individuals enrolled in the trial), and all were of insufficient sample size to draw clear conclusions. Rasmussen did not draw any firm conclusion from these data.
One relatively large trial was recently completed in rural Nepal, where the incidence of pregnancy anaemia and perinatal mortality are both high. This trial has only been reported in abstract form (Christian et al. 2002) and also was not sufficiently large to draw clear conclusions about perinatal mortality. However, it represents the strongest randomized trial evidence to date, because it was placebo-controlled and had high followup rates. In this trial, all women were provided anthelminthic treatment and vitamin A supplements. Women supplemented with 60 mg iron and 400 mg folic acid had 20% (95% CI 0.55-1.17) lower incidence of perinatal mortality than the placebo group (P. Christian, personal communication) . This point estimate is larger than the per cent reduction we estimated in this analysis (i.e. 16%, 95% CI 10-22%). However, the trial also included several additional treatment arms, including one group that received folic acid without iron. The folic acid-supplemented group also had lower perinatal mortality rates than the placebo group, a reduction of 11% (95% CI 0.63-1.26). Micronutrient supplementation began after the first trimester of pregnancy, and therefore these reductions cannot be attributed to the demonstrated effects of folic acid in preventing neural tube defects. Although neither of these reductions is statistically significant, they are important public health findings. If we accept these point estimates as the best available estimates from trial data, we conclude that our perinatal risk estimates are in accord with the benefits seen with effective iron-folic acid supplementation, but that a large part of the benefit may in fact be attributable to the folic acid.
The biological mechanisms linking iron deficiency anaemia (or anaemia from any cause) to perinatal mortality remain to be elucidated. One possible pathway is through preterm delivery. Recent reviews of clinical trial evidence have found the evidence inconclusive in support of a role for iron supplementation in preventing preterm birth or low birth weight (Mahomed 2000b; Rasmussen 2001) . However, the evidence for or against is remarkably weak, and does not rule out a causal relationship (Stoltzfus 2001) . Scott Poe and Mary Cogswell (personal communication) have recently completed a meta-analysis of the observational evidence relating pregnancy anaemia to low birth weight, intrauterine growth retardation and preterm birth. They found that pregnancy anaemia assessed in the first two trimesters of pregnancy was more strongly associated with preterm birth than intrauterine growth retardation or low birth weight, and that the risk of preterm birth increased with increasing severity of anaemia. Thus, while controlled trial evidence is lacking, the observational evidence suggests that preterm birth is one plausible mechanism for the anaemia-related risk of perinatal mortality.
If we accept preterm birth as a plausible causal pathway, the question remains as to how iron deficiency anaemia causes preterm birth. Allen suggested three possible mechanisms (Allen 2001) . Iron deficiency anaemia might activate a hormonal stress response, might increase oxidative stress or might increase the risk of maternal infections. Further research is needed to elucidate these mechanisms or to suggest alternative ones.
While preterm birth may be considered the leading hypothesis to explain the link between maternal anaemia and perinatal mortality, it is not the only hypothesis that should be pursued. If these above proposed mechanisms exist, it is plausible that they cause adverse effects on the fetus that go beyond preterm birth, for example by impairing the neonatal immune system, endocrine function, temperature regulation, or other systems critical to a successful transition from intra to extrauterine life. Additionally, the adverse effects of maternal anaemia on the mother's function and well-being may also increase risks to her neonate through her decreased capacity to actively care for and breastfeed the infant (Henly et al. 1995) . In the extreme case, maternal death associated with anaemia would increase the neonate's risk of death.
We included here an estimate of the continuous relationship between iron deficiency anaemia in early childhood and later intelligence, even though this relationship is included in the direct disability score attributed to iron deficiency anaemia. The possible biological mechanisms underlying this relationship are the subject of a large body of ongoing research in animals and children (e.g. see Beard 2001) . To date, two published placebo-controlled randomized trials have measured the effect of longer-term (i.e. >2 months) iron supplementation on cognitive development of young children in samples that included anaemic children (Idjradinata and Pollitt 1993; Stoltzfus et al. 2001 ). Both trials found significant benefits in the iron-supplemented group. In Indonesia (Idjradinata and Pollitt 1993), the positive effect was measured on the Bayley Scales of Infant Development, while in Zanzibar , parental reports of motor and language milestones were used. These trials support a causal link between iron deficiency anaemia and child development that is at least partly preventable with early treatment.
The major difficulty has been quantifying this relationship in meaningful epidemiological and socioeconomic terms, especially in the sociocultural contexts in which iron deficiency anaemia is most prevalent. Our estimated OR is an attempt to put the relationship in epidemiological terms. This estimate relies on the assumption that a mean shift in IQ can be converted into increased risk of mild mental retardation, assuming that the entire IQ distribution was shifted equally. To our knowledge there has been only one published report of the relationship between early childhood anaemia and mild mental retardation as a dichotomous outcome (as opposed to intelligence or developmental scores as continuous outcomes). Hurtado et al. (1999) assessed the association between haemoglobin concentration of children in the United States enrolled in the Special Supplemental Program for Women, Infants, and Children, a programme of the U.S. Government that provides food supplements to low-income pregnant women and their young children (Hurtado et al. 1999) . After adjusting for several important covariates, the OR for mild or moderate mental retardation at school age remained significant in their model, which treated haemoglobin concentration as a continuous risk factor (as did ours). This finding supports the plausibility of our assumption that the association between mean cognitive scores and anaemia is associated with increased risks of mild mental retardation. However, it is only a single observational study, and we believe our estimate should be interpreted with extreme caution.
In summary, the available evidence suggests that iron deficiency anaemia contributes substantially to death and disability in the world. The great majority of this disease burden is in Africa and Asia and derives from anaemia in pregnancy and early childhood. This evidence is based on critical assumptions, most importantly, that the observed prospective relationships are causal in nature, and that the relationships analysed using anaemia as the risk factor pertain equally to iron deficiency anaemia as one particular form of anaemia.
The high global prevalence of anaemia and its potentially associated disease burden, as reflected in these estimates, constitute an urgent agenda for both research and action. First, we must clarify the assumptions above, the first and foremost of these being causality, and refine these estimates with stronger evidence. Because these estimates are uncertain in many respects, their most important use may be to motivate public health scientists to provide definitive causal evidence. Second, we must establish ways to effectively reduce iron deficiency anaemia to prevent these apparent consequences. We hope these new estimates of the burden of disease due to iron deficiency will motivate these actions.
Notes
